CNSP News and Press, CNS Pharmaceuticals Inc. From 09/30/21

An individual’s lifetime risk of developing a spinal cord or malignant brain tumor is under 1%. The American Cancer Society reveals that even when primary brain tumors do occur, more than half of them are benign, which means that they are not cancerous. Dr. Alyx B. Porter, a neuro...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced the dosing of the first patients in its Berubicin clinical d...

CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate, in the Potentially Pivotal Study for the Treatment of Glioblastoma Multiforme (GBM) Company continues to drive further patient enrollment with 9 clinical trial sites in...

A study led by researchers from the Arnold School of Public Health at the University of South Carolina has discovered that in comparison to patients lacking continuity of care , individuals with continuity in their primary health care have lower mortality rates. The study was published in...

A recently conducted study has found that in comparison with low-grade gliomas, high-grade gliomas in canines contain more immune cells linked to suppressing immune response. The study adds to evidence suggesting that these tumors may recruit immune cells which assist with immunosuppressio...

A study conducted by researchers from NeuRA and the University of New South Wales Sydney has found that individuals with chronic pain have a neurotransmitter imbalance in the area of the brain that is responsible for regulating emotions . The study was published in the “European Jour...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today reported its financial results for the quarter ended June 30, 2021. Th...

CNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook Recently granted FDA Fast Track Designation for Berubicin for treatment of recurrent Glioblastoma Multiforme (GBM) provides an accelerated pathway to potential approval and commercial...

Scientists from the Cancer Research UK Cambridge Institute have designed tests that can detect the presence of a type of brain tumor known as a glioma via a patient’s blood plasma or urine. The group notes that this test is the first of its kind globally , adding that its results, ...

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. Over recent months, the company has achieved several milestones demonstrating its operational, f...